跳至主要内容
临床试验/JPRN-UMIN000052532
JPRN-UMIN000052532已完成Unknown

Clinical pharmacological test of calcium alginate capsules -Optimization study of postprandial serum triglyceride elevation suppression effect (additional preliminary study)- - Optimization test of postprandial serum triglyceride elevation suppression effect of calcium alginate capsules (additional preliminary study).

Takasaki University of Health and Welfare0 个研究点目标入组 9 人开始时间: 2023年10月20日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
入组人数
9

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Persons receiving treatment, medication, or lifestyle guidance from a doctor due to dyslipidemia or diabetes. People who regularly use medicines, health foods, or supplements that affect blood lipids. Persons who have some kind of disease and are receiving medication and are deemed unsuitable as subjects by the research doctor. Persons who may have allergic symptoms related to rubber or latex. Persons who may develop allergic symptoms regarding fat-loaded foods (corn oil, etc.). Persons whose HIV antigen/antibody, HBs antigen, HCV antibody, or syphilis test result was positive at the time of screening. Persons with obvious abnormalities found in hematological or biochemical tests. Those who are pregnant, wish to become pregnant during the test, or are breastfeeding. Persons whose TG delta C3h (estimated TGCmax) is less than 30 mg/dL in the screening test. Those who have been diagnosed with bronchial asthma and are receiving treatment, or those who have received treatment in the past.

研究者

相似试验

Clinical pharmacological test of calcium alginate... | 临床试验